Recent Updates in Bispecific Therapies for Patients With Relapsed/Refractory Multiple Myeloma : Episode 3
MajesTEC-1: Identifying the Optimal Patient Population for Teclistamab
Panelists discuss how long-term follow-up data from MajesTEC-1 demonstrates teclistamab’s sustained efficacy and safety profile while identifying optimal candidates based on factors like prior therapy exposure, disease characteristics, and fitness level.
Video content above is prompted by the following:
- Long-Term Follow-Up From the Phase 1/2 MajesTEC-1 Trial of Teclistamab
- Is there a patient population who would benefit most from this treatment regimen?
Newsletter
Stay up to date on recent advances in the multidisciplinary approach to cancer.
Recent Videos
Related Content
